These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 36292642)
1. Unravelling Tumour Microenvironment in Melanoma at Single-Cell Level and Challenges to Checkpoint Immunotherapy. Bai X; Quek C Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292642 [TBL] [Abstract][Full Text] [Related]
2. High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. Quek C; Bai X; Long GV; Scolyer RA; Wilmott JS Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34681023 [TBL] [Abstract][Full Text] [Related]
3. Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma. Fattore L; Ruggiero CF; Liguoro D; Mancini R; Ciliberto G Cell Death Dis; 2019 Oct; 10(11):827. PubMed ID: 31672982 [TBL] [Abstract][Full Text] [Related]
4. Single-cell RNA sequencing in melanoma: what have we learned so far? Lim SY; Rizos H EBioMedicine; 2024 Feb; 100():104969. PubMed ID: 38241976 [TBL] [Abstract][Full Text] [Related]
5. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Habashy KJ; Mansour R; Moussalem C; Sawaya R; Massaad MJ Br J Cancer; 2022 Oct; 127(6):976-987. PubMed ID: 35662275 [TBL] [Abstract][Full Text] [Related]
8. NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma. Li H; Zhang Q; Duan Q; Tan Y; Sun T; Qi C Front Immunol; 2022; 13():894110. PubMed ID: 35967450 [TBL] [Abstract][Full Text] [Related]
9. The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology. Wienke J; Dierselhuis MP; Tytgat GAM; Künkele A; Nierkens S; Molenaar JJ Eur J Cancer; 2021 Feb; 144():123-150. PubMed ID: 33341446 [TBL] [Abstract][Full Text] [Related]
10. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance. Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269 [TBL] [Abstract][Full Text] [Related]
11. The role of the tumour microenvironment in immunotherapy. Gasser S; Lim LHK; Cheung FSG Endocr Relat Cancer; 2017 Dec; 24(12):T283-T295. PubMed ID: 28754821 [TBL] [Abstract][Full Text] [Related]
12. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation. Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W Front Immunol; 2022; 13():998266. PubMed ID: 36248785 [TBL] [Abstract][Full Text] [Related]
14. The tumour immune landscape and its implications in cutaneous melanoma. Attrill GH; Ferguson PM; Palendira U; Long GV; Wilmott JS; Scolyer RA Pigment Cell Melanoma Res; 2021 May; 34(3):529-549. PubMed ID: 32939993 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of immune activation and regulation: lessons from melanoma. Kalaora S; Nagler A; Wargo JA; Samuels Y Nat Rev Cancer; 2022 Apr; 22(4):195-207. PubMed ID: 35105962 [TBL] [Abstract][Full Text] [Related]
16. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071 [TBL] [Abstract][Full Text] [Related]
17. Tumour neoantigen heterogeneity thresholds provide a time window for combination immunotherapy. Aguadé-Gorgorió G; Solé R J R Soc Interface; 2020 Oct; 17(171):20200736. PubMed ID: 33109023 [TBL] [Abstract][Full Text] [Related]
18. Novel Targets for the Treatment of Melanoma. Ambrosi L; Khan S; Carvajal RD; Yang J Curr Oncol Rep; 2019 Nov; 21(11):97. PubMed ID: 31696329 [TBL] [Abstract][Full Text] [Related]
19. Microenvironmental regulation of tumour immunity and response to immunotherapy. Kockx MM; McCleland M; Koeppen H J Pathol; 2021 Jul; 254(4):374-383. PubMed ID: 33846997 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade. Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]